Environment &
Food & Beverage
Cosmetics
Life Sciences
Metal & Mining Industry
Petrochemical & General Chemistry
Automotive Related & Interior Materials
InertSearch (Application Library)
Index
Application
LC
Document No. Index
LB101 - 200 of Application List
| No. | Description | Column |
|---|---|---|
| LB101 | Analysis of Brotizolam (Under the Condition of the Japanese Pharmacopoeia, Brotizolam tablets) | Inertsil WP300 C18 |
| LB102 | Analysis of Donepezil hydrochloride (Under the Condition of Japanese Pharmacopoeia, Donepezil hydrochloride tablets) | Inertsil ODS-2 |
| LB103 | Analysis of Pilsicainide hydrochloride hydrate (Under the Condition of the Japanese Pharmacopoeia) | Inertsil ODS-4 |
| LB104 | Analysis of Pitavastatin calcium (Under the Condition of the Japanese Pharmacopoeia, Pitavastatin calcium hydrate) | Inertsil ODS-4 |
| LB105 | Analysis of Pitavastatin calcium | Inertsil ODS-4 |
| LB106 | Analysis of Pitavastatin calcium tablets (Under the Condition of the draft for the Japanese Pharmacopoeia) | Inertsil ODS-4 |
| LB107 | Analysis of Pre-column Derivatized Aflatoxin | InertSustain C18 |
| LB109 | Analysis of Organic acids (InertSustain C18) | InertSustain C18 |
| LB110 | Analysis of Organic acids (Inertsil ODS-4) | Inertsil ODS-4 |
| LB111 | Analysis of Sivelestat sodium hydrate (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB112 | Analysis of Sivelestat sodium hydrate (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB113 | Analysis of Epalrestat (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB114 | Analysis of Epalrestat (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB115 | Analysis of Mecobalamin (Under the Condition of the Japanese Pharmacopoeia, Mecobalamin Tablets) | Inertsil ODS-4 |
| LB116 | Analysis of Mecobalamin (Under the Condition of the Japanese Pharmacopoeia, Mecobalamin Tablets) | Inertsil ODS-4 |
| LB117 | Analysis of Mecobalamin (Under the Condition of the Japanese Pharmacopoeia, Mecobalamin Tablets) | Inertsil ODS-4 |
| LB118 | Analysis of Glimepiride (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-3 |
| LB119 | Analysis of Glimepiride (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-3 |
| LB120 | Analysis of Simvastatin (Under the Condition of the Japanese Pharmacopoeia, Simvastatin Tablets) | Inertsil WP300 C18 |
| LB121 | Analysis of Simvastatin (Under the Condition of the Japanese Pharmacopoeia, Simvastatin Tablets) | Inertsil WP300 C18 |
| LB122 | Analysis of Simvastatin (Under the Condition of the Japanese Pharmacopoeia, Simvastatin Tablets) | Inertsil WP300 C18 |
| LB123 | Analysis of Ipriflavone (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C8 |
| LB124 | Analysis of Ipriflavone (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C8 |
| LB125 | Analysis of Risperidone (Under the Condition of the Japanese Pharmacopoeia, Risperidone Tablets) | Inertsil WP300 C18 |
| LB126 | Analysis of Risperidone (Under the Condition of the Japanese Pharmacopoeia, Risperidone Tablets) | Inertsil WP300 C18 |
| LB127 | Analysis of Etizolam (Under the Condition of the Japanese Pharmacopoeia, Etizolam Tablets) | Inertsil ODS-3 |
| LB128 | Analysis of Teprenone (Under the Condition of the Japanese Pharmacopoeia, Teprenone Capsules) | Inertsil ODS-2 |
| LB129 | Analysis of Amantadine (Inertsil HILIC) | Inertsil HILIC |
| LB130 | Analysis of Amantadine (InertSustain C18) | InertSustain C18 |
| LB133 | Analysis of Fexofenadine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) | Inertsil Ph |
| LB134 | Analysis of Fexofenadine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) | Inertsil Ph |
| LB135 | Analysis of Methylhippuric acid | InertSustain Phenyl |
| LB136 | Analysis of Cresol | InertSustain Phenyl |
| LB137 | Analysis of Estrogen | InertSustain Phenyl |
| LB138 | Analysis of Steroidal anti-inflammatory drug | InertSustain Phenyl |
| LB139 | Analysis of Nonsteroidal anti-inflammatory drug | InertSustain Phenyl |
| LB140 | Analysis of Sugar | InertSustain NH2 |
| LB141 | Analysis of Cyclodextrin | InertSustain NH2 |
| LB142 | Analysis of Sugar alcohol | InertSustain NH2 |
| LB143 | Analysis of Nucleobase | InertSustain NH2 |
| LB144 | Analysis of Glucosamine | InertSustain NH2 |
| LB145 | Analysis of Acarbose | InertSustain NH2 |
| LB146 | Analysis of Acesulfame potassium | InertSustain NH2 |
| LB147 | Analysis of Allantoin | InertSustain NH2 |
| LB148 | Analysis of Cyanocobalamin (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C8 |
| LB149 | Analysis of Liner alkylbenzene sulfonate (InertSustain C18 HP) | InertSustain C18 HP |
| LB150 | Analysis of Liner alkylbenzene sulfonate (Inertsil C8-4 HP) | Inertsil C8-4 HP |
| LB151 | Analysis of Liner alkylbenzene sulfonate (InertSustain C18 HP) | InertSustain C18 HP |
| LB152 | Analysis of Epinastine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Epinastine Hydrochloride Tablets) | Inertsil C8-4 |
| LB153 | Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Amlodipine besylate Tablets) | Inertsil ODS-SP |
| LB154 | Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Amlodipine besylate Tablets) | Inertsil ODS-4 |
| LB155 | Analysis of Amlodipine besylate (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Amlodipine besylate Tablets) | Inertsil ODS-4 |
| LB156 | Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Amlodipine besylate Tablets) | Inertsil ODS-4 |
| LB157 | Analysis of Clopidogrel sulfate (InertSustain C18) (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB158 | Analysis of Clopidogrel sulfate (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia) | Inertsil WP300 C18 |
| LB159 | Analysis of Clopidogrel sulfate (InertSustain C18) (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB160 | Analysis of Clopidogrel sulfate (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia) | Inertsil WP300 C18 |
| LB161 | Analysis of Clopidogrel sulfate (InertSustain C18) (Under the Condition of the Japanese Pharmacopoeia, Clopidogrel sulfate Tablets) | InertSustain C18 |
| LB162 | Analysis of Clopidogrel sulfate (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia, Clopidogrel sulfate Tablets) | Inertsil WP300 C18 |
| LB163 | Analysis of Telmisartan (Under the Condition of the Japanese Pharmacopoeia) | Inertsil ODS-SP |
| LB164 | Analysis of Telmisartan (Under the Condition of the Japanese Pharmacopoeia, Telmisartan Tablets) | Inertsil ODS-4 |
| LB165 | Analysis of Pravastatin Sodium (Under the Condition of the Japanese Pharmacopoeia, Pravastatin Sodium Tablets) | Inertsil ODS-4 |
| LB166 | Analysis of Pravastatin Sodium (Under the Condition of the Japanese Pharmacopoeia,Pravastatin Sodium Tablets) | Inertsil WP300 C18 |
| LB167 | Analysis of Crospovidone (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB171 | Analysis of Protein | Monocap C18 Fast-flow |
| LB172 | Analysis of Tryptophan metabolites | Monocap C18 Fast-flow |
| LB173 | Analysis of Azelastine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB174 | Analysis of d-Chlorpheniramine maleate (Under the Condition of the Japanese Pharmacopoeia) | Inertsil ODS-3 |
| LB175 | Analysis of Loxoprofen (Under the Condition of the Japanese Pharmacopoeia, Loxoprofen sodium Tablets) | InertSustain C18 |
| LB176 | Analysis of Povidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (4) 1-Vinyl-2-pyrrolidone) | InertSustain C18 |
| LB177 | Analysis of Povidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (8) 2-pyrrolidone) | InertSustain C18 |
| LB178 | Analysis of Hydrochlorothiazide | Inertsil WP300 C18 |
| LB179 | Analysis of Erythromycin | Inertsil ODS-4 HP |
| LB180 | Analysis of Sugars | InertSustain NH2 |
| LB181 | Analysis of Glycyrrhiza (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB182 | Analysis of Glycyrrhiza (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB183 | Analysis of Phellodendron Bark (InertSustain C18) (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB184 | Analysis of Phellodendron Bark (Inertsil ODS-3) (Under the Condition of the Japanese Pharmacopoeia) | Inertsil ODS-3 |
| LB185 | Analysis of Chlorpheniramine maleate (Under the Condition of the Japanese Pharmacopoeia,Chlorpheniramine maleate Tablets) | InertSustain C18 |
| LB186 | Analysis of Chlorpheniramine maleate (Under the Condition of the Japanese Pharmacopoeia,Chlorpheniramine maleate Tablets) | InertSustain C18 |
| LB187 | Analysis of Chlorpheniramine maleate (Under the Condition of the Japanese Pharmacopoeia,Chlorpheniramine maleate Tablets) | InertSustain C18 |
| LB188 | Analysis of Pioglitazone hydrochloride (Inertsil C8-3) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) | Inertsil C8-3 |
| LB189 | Analysis of Pioglitazone hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) | InertSustain C8 |
| LB190 | Analysis of Metformin hydrochloride (Inertsil C8-3) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) | Inertsil C8-3 |
| LB191 | Analysis of Metformin hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) | InertSustain C8 |
| LB192 | Analysis of Pioglitazone hydrochloride (Inertsil C8-3) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) | Inertsil C8-3 |
| LB193 | Analysis of Pioglitazone hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) | InertSustain C8 |
| LB194 | Analysis of Metformin hydrochloride (Inertsil C8-3) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) | Inertsil C8-3 |
| LB195 | Analysis of Metformin hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) | InertSustain C8 |
| LB196 | Analysis of Ciprofloxacin hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Ciprofloxacin hydrochloride hydrate) | InertSustain C18 |
| LB198 | Analysis of Steroidal anti-inflammatory drug | InertSustain Phenyl |
| LB199 | Analysis of Vitamin E | Inertsil NH2 |
| LB200 | Analysis of Losartan potassium and Hydrochlorothiazide (Under the Condition of USP 35-NF30, Losartan potassium and Hydrochlorothiazide Tablets) | Inertsil C8-3 |